China Pharma
China’s Pharmaceutical Renaissance: Bispecific Antibodies, Innovation, and Global Impact (2015–2024)
China’s pharma industry transformed (2015–2024) into a global hub with 4,382 drug candidates, $9.26B in BsAb deals, and 2025 FDA approvals like Sunvozertinib, Taletrectinib, and Penpulimab. With $130.4B in PD-1/VEGF and other deals, plus CGT advances, it’s reshaping pharma.